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A prospective multicentre clinical study was initiated to evaluate the safety and potential clinical benefit of non-
invasive vagus nerve stimulation (nVNS) for the treatment of bronchoconstriction exacerbations in asthmatics. Due
to slow enrolment and design changes of the device, the study was prematurely terminated after enrolment of
four eligible patients. Three of the four patients were considered treatment successes based on improvement in
FEV1, improvement in VAS dyspnoea scoring, and the absence of device-related adverse events.
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Asthma remains a serious global health issue placing a
major burden on health care resources despite the
progress made in the methods of treatment and diag-
nosis of the disease [1,2]. The majority of treatment
options for asthma management are pharmacological;
however, a recent publication describes positive find-
ings with the use of a novel percutaneous vagus nerve
stimulator for treatment of acute severe asthma exac-
erbations [3]. In this letter, the authors report their
early experiences with an nVNS device for the relief of
acute bronchoconstriction in asthmatics treated in an
emergency department setting.
Independent ethics review board approval was granted
for the prospective multicentre study (South African
Medical Association Research Ethics Committee: Proto-
col No. BC-SA-01) and informed consent was obtained
for all study subjects. Subjects between the ages of 18 and
70 years were recruited from the pool of patients admitted
to the emergency departments at participating investiga-
tional sites with a diagnosis of bronchoconstriction due to
asthma. Enrolment criteria included a VAS dyspnoea score* Correspondence: esteyn@mweb.co.za
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in any medium, provided the original work is pof 3 or more with a failure to show at least a 1.5 point
improvement and an FEV1 of less than 60% predicted, fol-
lowing SOC treatment [SOC treatment included supple-
mental oxygen, inhaled β2 agonists (without ipratropium),
and/or inhaled corticosteroids]. Subjects received a total
of two nVNS treatments with the study device, 30 min
apart and each lasting 60 s. During this period, subjects
continued to receive standard pharmacological treatment
consistent with the standard of care at their institution as
required. Subjects were monitored at regular intervals to
determine changes in respiratory status and vital signs for
90 min post initial nVNS. The success criteria for the pri-
mary outcome measurements were an improvement of a
minimum of 12% above baseline in FEV1, an increase of at
least 1.5 points over baseline in the VAS dyspnoea score
immediately after the second nVNS and the absence of
any serious device-related adverse events.
Since study enrolment was significantly slower than an-
ticipated and a next-generation device had become avail-
able before enrolment could be completed; the decision
was taken to terminate the study after 4 eligible patients
out of the originally planned 25 patients had been treated.
However, findings for these patients were noteworthy and
are summarised in Table 1, Figures 1 and 2. Three subjects
were classified as treatment successes based on the prede-
fined definition. One subject satisfied the VAS dyspnoeaOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Table 1 Table showing the effect of nVNS on FEV1 (mean
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Figure 2 Effect of vagal nerve stimulation on work of breathing
(VAS) (n = 4).
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achieved an increase of 9% in FEV1. FEV1 in the four
treated subjects showed a mean improvement of 73% in-
crease over baseline at 90 min post-stimulation; similarly,
mean VAS decreased from a score of 8 pre-stimulation to
1 at 90 min. The mean heart rate was 106 pre-nVNS, with
a decrease to 85 at 90 min post-nVNS. Mean systolic
blood pressure increased by 4% after the first nVNS, but
decreased at 60 and 90 min post-nVNS to lower levels
than pre-nVNS. One patient experienced an adverse
event, a previously diagnosed respiratory tract infection
requiring antibiotic treatment on admission to the unit,
unrelated to the device or procedure.
Although the traditional view has held that stimulation
of the vagus nerve results in increased airway resistance
and decreased compliance [4,5], an electrical stimulus sig-
nal that reduced histamine-induced bronchoconstriction in
guineapig and swine has recently been described [6]. This
is a relatively low amplitude signal, significantly below the
threshold required to stimulate efferent vagus fibres that
would evoke bronchoconstriction or bradycardia [6]. Our
results support the recent findings of Miner et al., who
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Figure 1 Effect of vagal nerve stimulation on FEV1 (n = 4).breathing, little impact on haemodynamic stability, and the
absence of serious adverse events when using a percutan-
eous device for vagal nerve stimulation in 25 patients with
asthma exacerbations reporting to the emergency depart-
ment [3].
From a user perspective, the non-invasive device has
obvious advantages over the percutaneous device, which
requires experience with both the placement of central
venous lines and the possibility of the occurrence of
concomitant adverse events. Furthermore, compared to
the traditional pharmacological treatment, there are se-
veral potential benefits of using a non-invasive device
with the possibility of eliminating side effects associated
with the use of drugs. The outcomes presented from the
cases treated in this report suggest that nVNS may be a
feasible nonpharmacological treatment option for the
management of acute asthma. RCTs of the nVNS device
are currently planned.60 75 90 
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